Meaningful patient representation informing Canada’s cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review

Jeffrey S Hoch, M. B. Brown, C. McMahon, J. Nanson, J. Nanson, L. Rozmovits

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

In this interview with the patient representatives on the Expert Review Committee (perc) of the Pan- Canadian Oncology Drug Review (pcodr), those representatives offer their views about how to be a valuable contributing member of Canada’s national cancer drug funding recommendation committee. The article seeks to inform readers, and especially clinicians, about pcodr from the perspective of the patient representatives.

Original languageEnglish (US)
Pages (from-to)263-266
Number of pages4
JournalCurrent Oncology
Volume21
Issue number5
DOIs
StatePublished - 2014
Externally publishedYes

Keywords

  • Health economics
  • Oncology drug funding
  • Pcodr

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Meaningful patient representation informing Canada’s cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review'. Together they form a unique fingerprint.

  • Cite this